OrthoPediatrics (KIDS) Moves 9.1% Higher: Will This Strength Last?

OrthoPediatrics KIDS shares rallied 9.1% in the last trading session to close at $61.49. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 16.4% gain over the past four weeks.

OrthoPediatrics recorded a strong price increase driven by its encouraging first-quarter 2021 results, with revenues surpassing Zacks Consensus Estimate by 8.5%. The company raising the lower-end of its full year 2021 revenue guidance also augers well. The company’s strong segmental performances driving the top line during the first quarter and expansion of international agencies raise optimism.

Price and Consensus

Price Consensus Chart for KIDS
Price Consensus Chart for KIDS

This maker of orthopedic devices is expected to post quarterly loss of $0.18 per share in its upcoming report, which represents a year-over-year change of +61.7%. Revenues are expected to be $23.9 million, up 75.8% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

For OrthoPediatrics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on KIDS going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

OrthoPediatrics Corp. (KIDS) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research